SYK vs MDLN stock comparison
Stryker vs. Medline · data as of November 13, 2026
Stryker (SYK) has a market value of about $117.9B, Medline (MDLN) about $51.9B. Over their latest twelve months Stryker had revenue of $26.3B and Medline $30.7B.
On our five checks Stryker scores higher: 2.8 out of 5 (average) against 1.0 (weak).
By area, the stronger company is Stryker on future growth; Stryker on track record; Stryker on financial health; Stryker on shareholder returns.
Stryker is cheaper on earnings (P/E 33.0 vs. 89.7).
Stryker leads on 17 of the compared lines and Medline on 4.
Side by side
| SYK | MDLN | |
|---|---|---|
| Size and price | ||
| Market cap | $117.9B | $51.9B |
| Share price | $309.64 | $39.47 |
| Score | ||
| Overall score (of 5) | 2.8 | 1.0 |
| Value | 0 | 0 |
| Future growth | 4 | 2 |
| Track record | 3 | 0 |
| Financial health | 3 | 2 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | 33.0 | 89.7 |
| Forward P/E | 18.9 | 26.2 |
| Price / free cash flow | 25.8 | 27.4 |
| Price / sales | 4.5 | 1.7 |
| EV / EBITDA | 18.5 | 22.6 |
| PEG | 2.22 | — |
| DCF value vs. price | −38% | −48% |
| Business | ||
| Revenue | $26.3B | $30.7B |
| Net income | $3.6B | $566M |
| Free cash flow | $4.6B | $1.9B |
| Net margin | 13.8% | 1.8% |
| Gross margin (5-yr avg.) | 63.7% | 26.4% |
| ROIC (5-yr avg.) | 9.0% | 8.6% |
| Growth | ||
| Revenue growth (1 yr) | 11.2% | 11.5% |
| Revenue growth (5 yrs, per year) | 11.8% | — |
| EPS growth (5 yrs, per year) | 14.9% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$12.2B | -$9.1B |
| Dividend yield | 1.14% | None |
| Shareholder yield | 1.1% | 0.1% |
| Analysts | ||
| Upside to average target | +10% | +15% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: SYK TTM to September 30, 2026, MDLN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Stryker or Medline?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Stryker scores 2.8 out of 5 and Medline 1.0; the table shows where each one is stronger.
Is Stryker cheaper than Medline?
On trailing earnings, Stryker trades at a P/E of 33.0 and Medline at 89.7, so Stryker is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which pays a higher dividend?
Stryker yields 1.14% and Medline nothing (no dividend).
Full Stryker analysis → Full Medline analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.